| |
Patients fulfilling
|
|---|
| |
Both sets
|
ACR set only
|
AECG set only
|
Neither set
|
|---|
| |
(n = 27)
|
(n = 8)
|
(n = 15)
|
(n = 55)
|
|---|
|
Age (years)
|
60.7 ± 11.7
|
46.6 ± 15.8
|
59.3 ± 11.1
|
56.4 ± 14.5
|
|
Symptom duration (years)
|
9.5 ± 7.4
|
2.9 ± 2.4
|
4.7 ± 4.3
|
6.4 ± 5.7
|
|
Female
|
25 (92.6)
|
8 (100)
|
14 (93.3)
|
52 (94.5)
|
|
Xerophthalmia
|
26 (96.3)
|
6 (75.0)
|
14 (93.3)
|
50 (90.9)
|
|
Xerostomia
|
27 (100)
|
6 (75.0)
|
15 (100)
|
51 (92.7)
|
|
Salivary flow ≤0.1 ml/minute
|
18 (66.7)
|
0 (0)
|
10 (66.7)
|
16 (29.1)
|
|
Schirmer’s test ≤5 mm/5 minutes
|
22 (81.5)
|
1 (12.5)
|
12 (80.0)
|
13 (23.6)
|
|
OSS ≥3
|
24 (88.9)
|
6 (75.0)
|
0 (0)
|
19 (34.5)
|
|
Anti-SSA or anti-SSB positivity
|
18 (66.7)
|
4 (50.0)
|
4 (26.7)
|
1 (1.8)
|
|
ANA ≥1:320
|
25 (92.6)
|
5 (62.5)
|
8 (53.3)
|
18 (32.7)
|
|
RF positivity
|
14 (51.9)
|
4 (50.0)
|
1 (6.7)
|
6 (10.9)
|
|
Anti-SSA/SSB or RF plus ANA ≥1:320
|
21 (77.8)
|
4 (50.0)
|
4 (26.7)
|
1 (1.8)
|
|
Focus score ≥1
|
24 (88.9)
|
7 (87.5)
|
11 (73.3)
|
6 (10.9)
|
- Data presented as mean ± standard deviation or number (%). Xerophthalmia and xerostomia referred to subjective complaints from the patients. ACR, American College of Rheumatology; AECG, American–European Consensus Group; OSS, ocular staining score; ANA, antinuclear antibody; RF, rheumatoid factor.
